

TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS



HLC101B
August 2014

Yojana Jeevane
Project Analyst

ISBN: 1-56965-894-3

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY AND OBJECTIVE	2
SCOPE OF THE REPORT	2
INTENDED AUDIENCE	3
INFORMATION AND METHODOLOGY SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
<i>SUMMARY TABLE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, 2013-2019 (\$ MILLIONS)</i>	7
CHAPTER 3 TISSUE ENGINEERING AND REGENERATION	10
MARKET OVERVIEW	10
PROGRESS AND PROMISES FOR THE TISSUE ENGINEERING INDUSTRY	11
<i>FIGURE 1 TISSUE-ENGINEERING STRATEGIES</i>	12
REPLACING BODY PARTS THROUGH TISSUE ENGINEERING	13
NANOTECHNOLOGY FOR TISSUE REGENERATION	13
<i>FIGURE 2 POTENTIAL NANOTECHNOLOGY APPLICATIONS</i>	14
EFFECTS OF NANOTECHNOLOGY ON STEM CELL BEHAVIOUR FOR TISSUE REGENERATION	14
Nanoparticles	14
Nanoscaffolds	15
NANOTECHNOLOGY IN TISSUE REGENERATION APPLICATIONS	15
Bone and Cartilage Regeneration	15
Vascular Tissue Regeneration	15
Neural Tissue Regeneration	15
GENE THERAPIES AS PART OF THE FUTURE OF TISSUE ENGINEERING	16
PROGRESS	16
PROSPECTS	17
STEM CELL TECHNOLOGIES BOON TO TISSUE ENGINEERING	17
GOVERNMENT REGULATIONS AND LEGISLATIONS	18
U.S. AND EUROPEAN REGULATION FOR TISSUE ENGINEERING PRODUCTS	18
CHINESE REGULATION FOR TISSUE ENGINEERING	19
REGULATORY DIFFERENCES	20
<i>TABLE 1 REGULATORY APPROVAL DIFFERENCES BETWEEN THE U.S. AND EUROPE</i>	21
ETHICAL ISSUES REGARDING STEM CELL THERAPIES AND CORD BLOOD BANKING	21
Ethical Issues Regarding Cord Blood Banking	21
Ethical Issues in Cord Blood Stem Cell Therapies	22
IMPACT OF THE HEALTHCARE SYSTEM ON TISSUE ENGINEERING MARKET DEVELOPMENT	22

TOPIC	PAGE NO.
<i>TABLE 2 HEALTHCARE PROVISIONS BY COUNTRY, 2014</i>	23
PORTER'S FIVE FORCE ANALYSIS OF THE TISSUE ENGINEERING AND REGENERATION MARKET	24
<i>FIGURE 3 PORTER'S FIVE FORCE MODEL FOR TISSUE ENGINEERING PRODUCTS</i>	24
SUPPLIER BARGAINING POWER: MODERATE	24
BUYER BARGAINING POWER: LOW	25
THREATS FROM SUBSTITUTE PRODUCTS: LOW	25
THREATS FROM NEW ENTRANTS: HIGH	25
COMPETITION FROM INDUSTRY PLAYERS: HIGH	25
CLINICAL TRIALS	26
U.S. TISSUE ENGINEERING CLINICAL TRIALS	26
<i>TABLE 3 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING</i>	26
Completed Clinical Trials for Tissue Engineering	27
<i>TABLE 4 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING</i>	27
Conclusion	28
Terminated Clinical Trials for Tissue Engineering	29
<i>TABLE 5 U.S. TERMINATED CLINICAL TRIALS</i>	29
Conclusion	29
EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING	29
<i>TABLE 6 EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING</i>	30
Conclusion	30
MARKET DYNAMICS	31
DRIVERS	31
Emergence of Stem Cell Technology	31
<i>FIGURE 4 GROWTH IN DISEASE TREATED VERSUS CLINICAL TRIALS, 2008-2012 (NO. OF TRIALS AND TREATMENTS)</i>	31
Prominent Potential of Nanotechnology	32
Rise in Prevalence of Trauma Emergencies and Chronic Diseases	33
<i>TABLE 7 U.S. UNINTENTIONAL INJURIES FACTS, 2013 (NO./%)</i>	33
Advancement in Surgical Technologies and Monitoring Devices	33
<i>TABLE 8 REGENERATIVE MEDICINE INDUSTRY TRENDS, 2007-2011</i>	34
RESTRAINTS	34
Operational Inefficiency	34
Stringent Regulatory Policies and Ethical Issues	35
High Treatment Cost	35
STEM CELL APPLICATION OPPORTUNITIES	35
Classification of Stem Cells According to Their Ability to Differentiate	36
Getting Core Competency in Emerging Economies	36
CHAPTER 4 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY TECHNOLOGY	38
<i>TABLE 9 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY TECHNOLOGY, THROUGH 2019 (\$ MILLIONS)</i>	38
STEM CELL TECHNOLOGIES	38
<i>TABLE 10 GLOBAL STEM CELL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	40
STEM CELL SOURCES	40
STEM CELL EXTRACTION TECHNIQUES	41

TOPIC	PAGE NO.
ALTERED NUCLEAR TRANSFER	42
BLASTOMERE EXTRACTION	42
STEM CELL EXPANSION	42
STEM CELL DELIVERY	43
<i>TABLE 11 COMMONLY USED VEHICLES FOR STEM CELL DELIVERY</i>	44
Direct Surgical Intramyocardial Injection	44
EXISTING AND DEVELOPMENT-STAGE STEM CELL PRODUCTS	44
<i>TABLE 12 COMMERCIALIZED TISSUE ENGINEERING PRODUCT SALES, 2011 (\$ MILLIONS)</i>	45
Clinical Application of Stem Cell Technologies in the Commercial Market	45
Cardiovascular Repair	45
Neural Repair	45
Bone Repair	46
Skeletal Muscle Repair	46
Urologic Repair	46
CELL CULTURE TECHNOLOGIES	46
PROJECT NO. 1	48
Project Description	48
PROJECT NO. 2	48
Project Description	48
PROJECT NO. 3	49
Project Description	49
PROJECT NO. 4	49
Project Description	49
PROJECT NO. 5	49
Project Description	49
PROJECT NO. 6	50
Project Description	50
PROJECT NO. 7	50
Project Description	50
<i>TABLE 13 GLOBAL CELL CULTURE TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	51
IMMUNOPASSIVATION AND IMMUNOMODULATION	51
IMMUNOMODULATION	51
CELL ENCAPSULATION	52
<i>TABLE 14 GLOBAL IMMUNOPASSIVATION AND IMMUNOMODULATION TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	53
CHAPTER 5 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY MATERIALS	55
<i>TABLE 15 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY MATERIAL, THROUGH 2019 (\$ MILLIONS)</i>	55
SYNTHETIC MATERIALS	55
<i>TABLE 16 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	56
<i>TABLE 17 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	56

TOPIC	PAGE NO.
BIODEGRADABLE SYNTHETIC POLYMERS	56
<i>TABLE 18 BIODEGRADABLE POLYMER CLASSIFICATION</i>	57
<i>TABLE 19 GLOBAL BIODEGRADABLE SYNTHETIC POLYMER MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	58
MEDICAL POLY LACTIC ACID SCAFFOLD	58
<i>TABLE 20 COMMERCIAL POLYMERIC SCAFFOLD PRODUCTS</i>	59
<i>TABLE 21 GLOBAL SCAFFOLD MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	60
ARTIFICIAL VASCULAR GRAFT MATERIALS	60
Stem Cell Integration in Vascular Tissue Engineering	60
Extracellular Matrix ECM-Based Vascular Grafts	60
Cell Sheets without Scaffold Support	61
<i>TABLE 22 GLOBAL ARTIFICIAL VASCULAR GRAFT MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	61
HYDROGEL TECHNOLOGY	61
<i>TABLE 23 GLOBAL HYDROGEL TECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	62
BIOLOGICALLY DERIVED MATERIALS	62
<i>TABLE 24 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	63
<i>TABLE 25 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	63
COLLAGEN	63
<i>TABLE 26 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	64
<i>TABLE 27 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	64
Animal-Derived	65
Recombinant	65
XENOGENIC TISSUE	65
<i>TABLE 28 GLOBAL BIOLOGICALLY DERIVED XENOGENIC TISSUE MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	66
GENETICALLY ENGINEERED MATERIALS	66
<i>TABLE 29 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	66
<i>TABLE 30 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	66
DEOXYRIBONUCLEIC ACID TRANSFECTION VECTORS	67
<i>TABLE 31 GLOBAL DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	68
GENETICALLY MANIPULATED CELLS	68
<i>TABLE 32 GLOBAL GENETICALLY MANIPULATED CELL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	69
THREE-DIMENSIONAL POLYMER TECHNOLOGY	69
<i>TABLE 33 GLOBAL THREE-DIMENSIONAL POLYMER TECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	70
TRANGENICS	70
<i>TABLE 34 GLOBAL TRANSGENIC TECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	70
FIBROBLASTS	71

TOPIC	PAGE NO.
<i>TABLE 35 GLOBAL FIBROBLAST MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	71
NEURAL STEM CELLS	71
<i>TABLE 36 GLOBAL NEURAL STEM CELL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	72
GENE-ACTIVATED MATRICES	72
<i>TABLE 37 GLOBAL GENE-ACTIVATED MATRIX MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	73
CHAPTER 6 TISSUE ENGINEERING AND REGENERATION MARKET BY APPLICATION	75
<i>TABLE 38 GLOBAL TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	75
INTERNAL ORGAN REGENERATION	75
<i>TABLE 39 GLOBAL INTERNAL ORGAN REGENERATION APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	76
LIVER REGENERATION	76
<i>TABLE 40 U.S. LIVER FAILURE STATISTICS, 2011</i>	77
<i>TABLE 41 ARTIFICIAL LIVER SUPPORT SYSTEMS</i>	78
PANCREAS AND ISLET CELL REGENERATION	79
<i>TABLE 42 U.S. PANCREATIC CANCER AND DIABETES STATISTICS, 2010</i>	79
KIDNEY AND RENAL TUBULE REGENERATION	81
<i>TABLE 43 U.S. KIDNEY DISEASE STATISTICS, 2010</i>	82
ORTHOPEDIC APPLICATIONS	82
<i>TABLE 44 KEY FACTS REGARDING ORTHOPEDIC DISEASES, BY REGION</i>	82
<i>TABLE 45 GLOBAL ORTHOPEDIC APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	83
BONE REPAIR AND REPLACEMENT	83
<i>TABLE 46 BONE DAMAGE AND RELATED DISEASES, 2011 (MILLIONS)</i>	84
CARTILAGE AND CONNECTIVE TISSUE DAMAGE TREATMENT	84
TISSUE-ENGINEERED PRODUCTS FOR BONE DEFECTS	85
CARTILAGE REPAIR AND REPLACEMENT	87
<i>TABLE 47 GLOBAL CARTILAGE DAMAGE STATISTICS, 2007</i>	87
MENISCUS REPAIR AND REPLACEMENT	88
TENDON AND LIGAMENT REPAIR AND REPLACEMENT	88
TISSUE ENGINEERING FOR THE CENTRAL NERVOUS SYSTEM	89
TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM DISEASES	90
<i>TABLE 48 GLOBAL TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	91
NEUROSURGICAL	91
Cell Implants for Parkinson's Diseases	92
<i>TABLE 49 GLOBAL NEURODEGENERATIVE DISEASE STATISTICS, 2011</i>	93
Cell Transplants for Epilepsy Treatment	93
Stem Cell Therapy for Multiple Sclerosis	93
SPINAL CORD INJURY AND SPINAL DISC REPAIR AND REPLACEMENT	94
<i>TABLE 50 GLOBAL SPINAL CORD INJURY STATISTICS, 2011</i>	94
Spinal Cord Injury Treatments	94
Tissue Engineering for Spinal Cord Injury	95
Cell Therapy for Spinal Cord Injury	95
Scaffold Approach for Spinal Cord Injury Treatment	96
TISSUE ENGINEERING FOR CARDIOVASCULAR DISORDERS	97

TOPIC	PAGE NO.
<i>TABLE 51 GLOBAL CARDIOVASCULAR DISORDERS APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	98
PERIPHERAL VASCULAR DISEASE APPLICATIONS	98
CORONARY ARTERY DISEASE APPLICATIONS	99
Heart Valves and Tissue Engineering	100
Mechanical Heart Valves	100
Biological Heart Valves	100
<i>TABLE 52 COMPANIES DEVELOPING CELL THERAPIES FOR CARDIO VASCULAR DISORDERS, 2013</i>	101
DENTAL TISSUE ENGINEERING	102
<i>TABLE 53 GLOBAL DENTAL TISSUE ENGINEERING APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	103
DERMATOLOGY TISSUE ENGINEERING	103
<i>TABLE 54 U.S. AND GLOBAL SKIN DAMAGE MEDICAL CONDITION STATISTICS, 2011</i>	104
<i>TABLE 55 COMMERCIALIZED ACELLULAR SKIN TISSUE-ENGINEERED, 2014</i>	105
<i>TABLE 56 COMMERCIALIZED CELLULAR SKIN TISSUE ENGINEERED PRODUCTS</i>	105
<i>TABLE 57 GLOBAL DERMATOLOGY TISSUE ENGINEERING APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	107
WOUND MANAGEMENT	107
<i>TABLE 58 WOUND CARE MARKET BY CATEGORY (%)</i>	107
Burn Treatment	108
Ulcer Treatment	109
ANTI-AGING THERAPIES	110
OTHERS	110
<i>TABLE 59 GLOBAL OTHER APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	110
MUSCLE REGENERATION	110
<i>TABLE 60 IN VITRO VERSUS IN VIVO SKELETAL MUSCLE TISSUE ENGINEERING</i>	111
PERIPHERAL NERVE REPAIR	112
HERNIA AND SOFT TISSUE REPAIR	112
CHAPTER 7 TISSUE ENGINEERING AND REGENERATION MARKET BY REGION	114
<i>TABLE 61 COMPANIES OPERATING IN REGENERATIVE MEDICINES MARKET BY CONTINENT, 2011 (\$ MILLIONS)</i>	114
<i>TABLE 62 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	114
NORTH AMERICA	115
<i>TABLE 63 NORTH AMERICAN COMMERCIALIZED TISSUE ENGINEERING PRODUCTS, 2013</i>	115
<i>TABLE 64 NORTH AMERICAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 (\$ MILLIONS)</i>	119
U.S. SKIN TISSUE ENGINEERING PRODUCT MARKET	119
<i>TABLE 65 U.S. SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE, 2011</i>	119
U.S. CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET	120
<i>TABLE 66 U.S. BONE DAMAGE AND RELATED DISEASE STATISTICS, 2011</i>	121
U.S. TISSUE ENGINEERING PRODUCTS FOR CARDION VASCULAR DISORDERS MARKET	121
<i>TABLE 67 U.S. CARDIOVASCULAR DISORDER STATISTICS, 2010 AND 2011</i>	121
EUROPE	122

TOPIC	PAGE NO.
<i>TABLE 68 TISSUE ENGINEERING FIRMS BY TYPE, 2012 (%)</i>	122
<i>TABLE 69 EUROPEAN TISSUE ENGINEERING FIRMS BY REGION, 2012 (%)</i>	123
<i>TABLE 70 EUROPEAN SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE STATISTICS, 2011</i>	123
<i>TABLE 71 EUROPEAN COMPANIES SELLING OR DEVELOPING SKIN TISSUE-ENGINEERED PRODUCTS, 2013</i>	124
<i>TABLE 72 EUROPEAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 (\$ MILLIONS)</i>	125
EUROPEAN AND BONE TISSUE ENGINEERING PRODUCT MARKET	126
<i>TABLE 73 EUROPEAN BONE DAMAGE AND RELATED DISEASE MARKET BY COUNTRY</i>	126
EUROPEAN TISSUE ENGINEERING PRODUCTS FOR CARDIOVASCULAR DISORDERS MARKET	126
<i>TABLE 74 EUROPEAN CARDIOVASCULAR DISORDER STATISTICS, 2011</i>	127
<i>TABLE 75 EUROPEAN RATE OF DEATH FROM HEART DISEASE BY COUNTRY, 2011 (DEATHS PER 100,000 CASES)</i>	127
EUROPEAN TISSUE ENGINEERING PRODUCTS FOR CENTRAL NERVOUS SYSTEM-RELATED INJURIES AND DISORDERS MARKET	128
<i>TABLE 76 EUROPEAN CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES, 2011</i>	129
<i>TABLE 77 EUROPEAN SPINAL CORD INJURY AND PARKINSON'S DISEASE BY COUNTRY, 2011</i>	129
<i>TABLE 78 EUROPEAN STEM CELL POLICIES BY COUNTRY,</i>	130
<i>TABLE 79 EUROPEAN COMPANIES DEVELOPING PRODUCTS IN TISSUE ENGINEERING AND REGENERATION FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES</i>	131
EUROPEAN TISSUE ENGINEERING FOR INTERNAL ORGANS MARKET	131
ASIA-PACIFIC	132
<i>FIGURE 5 PATHWAY FOR DISSEMINATION OF REGENERATIVE MEDICINE</i>	133
<i>TABLE 80 ASIA-PACIFIC TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 (\$ MILLIONS)</i>	134
ASIA-PACIFIC CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET	134
ASIA-PACIFIC MARKET FOR CARDIOVASCULAR TISSUE ENGINEERING PRODUCTS	134
ASIA-PACIFIC SKIN TISSUE ENGINEERING PRODUCT MARKET	134
REST OF THE WORLD	135
<i>TABLE 81 GLOBAL SKIN-RELATED MEDICAL CONDITION STATISTICS, 2011</i>	135
<i>TABLE 82 REST OF WORLD TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 (\$ MILLIONS)</i>	137
REST OF THE WORLD CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET	137
REST OF WORLD TISSUE ENGINEERING PRODUCTS FOR CARDIOVASCULAR DISORDERS MARKET	138
<i>TABLE 83 GLOBAL CARDIOVASCULAR DISORDER STATISTICS, 2011</i>	138
<i>TABLE 84 REST OF THE WORLD COMPANIES THAT MANUFACTURE AND DEVELOP TISSUE-ENGINEERED PRODUCTS FOR CARDIOVASCULAR DISORDER, BY COUNTRY</i>	139
REST OF THE WORLD TISSUE ENGINEERING PRODUCTS FOR CENTRAL NERVOUS SYSTEM-RELATED INJURIES AND DISEASES MARKET	139
<i>TABLE 85 GLOBAL CENTRAL NERVOUS SYSTEM DISORDER AND INJURY STATISTICS, 2011</i>	140

TOPIC	PAGE NO.
CHAPTER 8 COMPETITIVE LANDSCAPE	142
<i>FIGURE 6 KEY COMPETITIVE STRATEGIES*, 2010-2014 (%)</i>	142
<i>TABLE 86 KEY COMPETITIVE STRATEGIES, 2010-2014 (%)</i>	143
APPROVAL	143
<i>FIGURE 7 APPROVAL STRATEGY BY COMPANY, 2010-2014 (%)</i>	144
<i>TABLE 87 APPROVAL STRATEGIES BY COMPANY, 2010-2014 (NO./%)</i>	145
<i>TABLE 88 KEY APPROVALS, 2010-2014</i>	145
AGREEMENTS, MERGERS AND ACQUISITIONS	146
<i>FIGURE 8 AGREEMENTS, MERGERS AND ACQUISITIONS, BY COMPANY, 2010-2014 (%)</i>	147
<i>TABLE 89 AGREEMENTS, MERGERS AND ACQUISITIONS BY COMPANY, 2010-2014 (%)</i>	148
<i>TABLE 90 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010-2014</i>	148
PRODUCT LAUNCHES AND CLINICAL TRIALS	149
<i>FIGURE 9 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%)</i>	150
<i>TABLE 91 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%)</i>	151
<i>TABLE 92 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010 AND 2014</i>	151
CHAPTER 9 PATENT ANALYSIS	153
<i>TABLE 93 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%)</i>	153
<i>FIGURE 10 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%)</i>	153
U.S. PATENT ANALYSIS BY MARKET PARTICIPANT	154
<i>TABLE 94 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)</i>	154
<i>FIGURE 11 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)</i>	154
U.S. PATENT ANALYSIS BY APPLICATIONS	155
<i>TABLE 95 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)</i>	155
<i>FIGURE 12 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)</i>	155
EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT	156
<i>TABLE 96 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)</i>	156
<i>FIGURE 13 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)</i>	156
EUROPEAN PATENT ANALYSIS BY APPLICATIONS	157
<i>TABLE 97 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)</i>	158
<i>FIGURE 14 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)</i>	158
JAPANESE PATENT ANALYSIS BY APPLICATION	158
<i>TABLE 98 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)</i>	159
<i>FIGURE 15 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)</i>	159
CHAPTER 10 COMPANY PROFILES	161
ADVANCED BIOHEALING (A SHIRE PHARMACEUTICAL COMPANY)	161
TISSUE ENGINEERING PRODUCT PORTFOLIO	161
<i>TABLE 99 ADVANCED BIOHEALING RECENT DEVELOPMENTS</i>	162
<i>TABLE 100 ADVANCED BIOHEALING FINANCIALS, 2011-2013 (\$ MILLIONS/%)</i>	162
ADVANCED CELL TECHNOLOGY INC.	162
TISSUE ENGINEERING PRODUCT PORTFOLIO	163
<i>TABLE 101 ADVANCED CELL TECHNOLOGY INC. RECENT DEVELOPMENTS</i>	163
ARTERIOCYTE	163
TISSUE ENGINEERING PRODUCT PORTFOLIO	163
<i>TABLE 102 ARTERIOCYTE RECENT DEVELOPMENTS</i>	164

TOPIC	PAGE NO.
ATHERSYS INC.	164
TISSUE ENGINEERING PRODUCT PORTFOLIO	164
<i>TABLE 103 ATHERSYS INC. RECENT DEVELOPMENTS</i>	165
<i>TABLE 104 ATHERSYS FINANCIALS, 2011-2013 (\$ MILLIONS/%)</i>	165
BIOHEART INC.	165
TISSUE ENGINEERING PRODUCT PORTFOLIO	166
<i>TABLE 105 BIOHEART INC. RECENT DEVELOPMENTS</i>	166
CERAPEDICS INC.	166
TISSUE ENGINEERING PRODUCT PORTFOLIO	167
<i>TABLE 106 CERAPEDICS INC. RECENT DEVELOPMENTS</i>	167
CO.DON AG	167
TISSUE ENGINEERING PRODUCT PORTFOLIO	168
<i>TABLE 107 CO.DON AG RECENT DEVELOPMENTS</i>	168
COOK MEDICAL INC.	168
TISSUE ENGINEERING PRODUCT PORTFOLIO	169
<i>TABLE 108 COOK MEDICAL INC. RECENT DEVELOPMENTS</i>	169
CRYOLIFE INC	169
TISSUE ENGINEERING PRODUCT PORTFOLIO	169
<i>TABLE 109 CRYO LIFE INC. RECENT DEVELOPMENTS</i>	170
CYTOGRAFT TISSUE ENGINEERING	170
TISSUE ENGINEERING PRODUCT PORTFOLIO	170
<i>TABLE 110 CYTOGRAFT TISSUE ENGINEERING RECENT DEVELOPMENTS</i>	171
CYTOMEDIX INC.	171
TISSUE ENGINEERING PRODUCT PORTFOLIO	171
<i>TABLE 111 CYTOMEDIX INC. RECENT DEVELOPMENTS</i>	172
CYTORI THERAPEUTICS INC.	172
TISSUE ENGINEERING PRODUCT PORTFOLIO	172
<i>TABLE 112 CYTORI THERAPEUTICS INC. RECENT DEVELOPMENTS</i>	173
<i>TABLE 113 CYTORI THERAPEUTICS FINANCIALS, 2011-2013 (\$ MILLIONS/%)</i>	173
GENZYME (A SANOFI COMPANY)	173
TISSUE ENGINEERING PRODUCT PORTFOLIO	174
<i>TABLE 114 GENZYME RECENT DEVELOPMENTS</i>	174
<i>TABLE 115 GENZYME FINANCIALS, 2011-2013 (\$ MILLIONS/%)</i>	174
KINETIC CONCEPTS INC.	174
TISSUE ENGINEERING PRODUCT PORTFOLIO	175
<i>TABLE 116 KINETIC CONCEPTS INC. RECENT DEVELOPMENTS</i>	175
<i>TABLE 117 KINETICS CONCEPTS FINANCIALS, 2011-2013 (\$ MILLIONS/%)</i>	175
MESOBLAST LTD.	176
TISSUE ENGINEERING PRODUCT PORTFOLIO	176
ORGANOGENESIS INC.	176
TISSUE ENGINEERING PRODUCT PORTFOLIO	176
ORTHOPEUTICS	177
WRIGHT MEDICAL TECHNOLOGY INC.	177
TISSUE ENGINEERING PRODUCT PORTFOLIO	177
<i>TABLE 118 WRIGHT MEDICAL TECHNOLOGY INC. RECENT DEVELOPMENTS</i>	178
<i>TABLE 119 WRIGHT MEDICAL TECHNOLOGY FINANCIALS, 2011-2013 (\$ MILLIONS/%)</i>	178

TOPIC	PAGE NO.
CHAPTER 11 PATENTS	180
<i>TABLE 120 NORTH AMERICAN PATENTS</i>	180
<i>TABLE 121 EUROPEAN PATENTS</i>	181
<i>TABLE 122 JAPANESE PATENTS</i>	182

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 REGULATORY APPROVAL DIFFERENCES BETWEEN THE U.S. AND EUROPE	21
TABLE 2 HEALTHCARE PROVISIONS BY COUNTRY, 2014	23
TABLE 3 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING	26
TABLE 4 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING	27
TABLE 5 U.S. TERMINATED CLINICAL TRIALS	29
TABLE 6 EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING	30
TABLE 7 U.S. UNINTENTIONAL INJURIES FACTS, 2013 (NO./%)	33
TABLE 8 REGENERATIVE MEDICINE INDUSTRY TRENDS, 2007-2011	34
TABLE 9 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY TECHNOLOGY, THROUGH 2019 (\$ MILLIONS)	38
TABLE 10 GLOBAL STEM CELL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	40
TABLE 11 COMMONLY USED VEHICLES FOR STEM CELL DELIVERY	44
TABLE 12 COMMERCIALIZED TISSUE ENGINEERING PRODUCT SALES, 2011 (\$ MILLIONS)	45
TABLE 13 GLOBAL CELL CULTURE TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	51
TABLE 14 GLOBAL IMMUNOPASSIVATION AND IMMUNOMODULATION TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	53
TABLE 15 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY MATERIAL, THROUGH 2019 (\$ MILLIONS)	55
TABLE 16 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	56
TABLE 17 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	56
TABLE 18 BIODEGRADABLE POLYMER CLASSIFICATION	57
TABLE 19 GLOBAL BIODEGRADABLE SYNTHETIC POLYMER MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	58
TABLE 20 COMMERCIAL POLYMERIC SCAFFOLD PRODUCTS	59
TABLE 21 GLOBAL SCAFFOLD MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	60
TABLE 22 GLOBAL ARTIFICIAL VASCULAR GRAFT MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	61
TABLE 23 GLOBAL HYDROGEL TECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	62
TABLE 24 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	63
TABLE 25 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	63
TABLE 26 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	64
TABLE 27 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	64
TABLE 28 GLOBAL BIOLOGICALLY DERIVED XENOGENIC TISSUE MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	66
TABLE 29 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	66

TABLE HEADING	PAGE NO.
TABLE 30 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	66
TABLE 31 GLOBAL DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	68
TABLE 32 GLOBAL GENETICALLY MANIPULATED CELL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	69
TABLE 33 GLOBAL THREE-DIMENSIONAL POLYMER TECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	70
TABLE 34 GLOBAL TRANSGENIC TECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	70
TABLE 35 GLOBAL FIBROBLAST MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	71
TABLE 36 GLOBAL NEURAL STEM CELL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	72
TABLE 37 GLOBAL GENE-ACTIVATED MATRIX MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	73
TABLE 38 GLOBAL TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	75
TABLE 39 GLOBAL INTERNAL ORGAN REGENERATION APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	76
TABLE 40 U.S. LIVER FAILURE STATISTICS, 2011	77
TABLE 41 ARTIFICIAL LIVER SUPPORT SYSTEMS	78
TABLE 42 U.S. PANCREATIC CANCER AND DIABETES STATISTICS, 2010	79
TABLE 43 U.S. KIDNEY DISEASE STATISTICS, 2010	82
TABLE 44 KEY FACTS REGARDING ORTHOPEDIC DISEASES, BY REGION	82
TABLE 45 GLOBAL ORTHOPEDIC APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	83
TABLE 46 BONE DAMAGE AND RELATED DISEASES, 2011 (MILLIONS)	84
TABLE 47 GLOBAL CARTILAGE DAMAGE STATISTICS, 2007	87
TABLE 48 GLOBAL TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	91
TABLE 49 GLOBAL NEURODEGENERATIVE DISEASE STATISTICS, 2011	93
TABLE 50 GLOBAL SPINAL CORD INJURY STATISTICS, 2011	94
TABLE 51 GLOBAL CARDIOVASCULAR DISORDERS APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	98
TABLE 52 COMPANIES DEVELOPING CELL THERAPIES FOR CARDIO VASCULAR DISORDERS, 2013	101
TABLE 53 GLOBAL DENTAL TISSUE ENGINEERING APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	103
TABLE 54 U.S. AND GLOBAL SKIN DAMAGE MEDICAL CONDITION STATISTICS, 2011	104
TABLE 55 COMMERCIALIZED ACELLULAR SKIN TISSUE-ENGINEERED, 2014	105
TABLE 56 COMMERCIALIZED CELLULAR SKIN TISSUE ENGINEERED PRODUCTS	105
TABLE 57 GLOBAL DERMATOLOGY TISSUE ENGINEERING APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	107
TABLE 58 WOUND CARE MARKET BY CATEGORY (%)	107
TABLE 59 GLOBAL OTHER APPLICATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	110
TABLE 60 IN VITRO VERSUS IN VIVO SKELETAL MUSCLE TISSUE ENGINEERING	111
TABLE 61 COMPANIES OPERATING IN REGENERATIVE MEDICINES MARKET BY CONTINENT, 2011 (\$ MILLIONS)	114
TABLE 62 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	114

TABLE HEADING	PAGE NO.
TABLE 63 NORTH AMERICAN COMMERCIALIZED TISSUE ENGINEERING PRODUCTS, 2013	115
TABLE 64 NORTH AMERICAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 (\$ MILLIONS)	119
TABLE 65 U.S. SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE, 2011	119
TABLE 66 U.S. BONE DAMAGE AND RELATED DISEASE STATISTICS, 2011	121
TABLE 67 U.S. CARDIOVASCULAR DISORDER STATISTICS, 2010 AND 2011	121
TABLE 68 TISSUE ENGINEERING FIRMS BY TYPE, 2012 (%)	122
TABLE 69 EUROPEAN TISSUE ENGINEERING FIRMS BY REGION, 2012 (%)	123
TABLE 70 EUROPEAN SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE STATISTICS, 2011	123
TABLE 71 EUROPEAN COMPANIES SELLING OR DEVELOPING SKIN TISSUE-ENGINEERED PRODUCTS, 2013	124
TABLE 72 EUROPEAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 (\$ MILLIONS)	125
TABLE 73 EUROPEAN BONE DAMAGE AND RELATED DISEASE MARKET BY COUNTRY	126
TABLE 74 EUROPEAN CARDIOVASCULAR DISORDER STATISTICS, 2011	127
TABLE 75 EUROPEAN RATE OF DEATH FROM HEART DISEASE BY COUNTRY, 2011 (DEATHS PER 100,000 CASES)	127
TABLE 76 EUROPEAN CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES, 2011	129
TABLE 77 EUROPEAN SPINAL CORD INJURY AND PARKINSON'S DISEASE BY COUNTRY, 2011	129
TABLE 78 EUROPEAN STEM CELL POLICIES BY COUNTRY,	130
TABLE 79 EUROPEAN COMPANIES DEVELOPING PRODUCTS IN TISSUE ENGINEERING AND REGENERATION FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES	131
TABLE 80 ASIA-PACIFIC TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 (\$ MILLIONS)	134
TABLE 81 GLOBAL SKIN-RELATED MEDICAL CONDITION STATISTICS, 2011	135
TABLE 82 REST OF WORLD TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 (\$ MILLIONS)	137
TABLE 83 GLOBAL CARDIOVASCULAR DISORDER STATISTICS, 2011	138
TABLE 84 REST OF THE WORLD COMPANIES THAT MANUFACTURE AND DEVELOP TISSUE-ENGINEERED PRODUCTS FOR CARDIOVASCULAR DISORDER, BY COUNTRY	139
TABLE 85 GLOBAL CENTRAL NERVOUS SYSTEM DISORDER AND INJURY STATISTICS, 2011	140
TABLE 86 KEY COMPETITIVE STRATEGIES, 2010-2014 (%)	143
TABLE 87 APPROVAL STRATEGIES BY COMPANY, 2010-2014 (NO./%)	145
TABLE 88 KEY APPROVALS, 2010-2014	145
TABLE 89 AGREEMENTS, MERGERS AND ACQUISITIONS BY COMPANY, 2010-2014 (%)	148
TABLE 90 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010-2014	148
TABLE 91 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%)	151
TABLE 92 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010 AND 2014	151
TABLE 93 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%)	153
TABLE 94 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)	154
TABLE 95 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)	155
TABLE 96 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)	156
TABLE 97 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)	158
TABLE 98 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)	159
TABLE 99 ADVANCED BIOHEALING RECENT DEVELOPMENTS	162
TABLE 100 ADVANCED BIOHEALING FINANCIALS, 2011-2013 (\$ MILLIONS/%)	162

TABLE HEADING	PAGE NO.
TABLE 101 ADVANCED CELL TECHNOLOGY INC. RECENT DEVELOPMENTS	163
TABLE 102 ARTERIOCYTE RECENT DEVELOPMENTS	164
TABLE 103 ATHERSYS INC. RECENT DEVELOPMENTS	165
TABLE 104 ATHERSYS FINANCIALS, 2011-2013 (\$ MILLIONS/%)	165
TABLE 105 BIOHEART INC. RECENT DEVELOPMENTS	166
TABLE 106 CERAPEDICS INC. RECENT DEVELOPMENTS	167
TABLE 107 CO.DON AG RECENT DEVELOPMENTS	168
TABLE 108 COOK MEDICAL INC. RECENT DEVELOPMENTS	169
TABLE 109 CRYO LIFE INC. RECENT DEVELOPMENTS	170
TABLE 110 CYTOGRAFT TISSUE ENGINEERING RECENT DEVELOPMENTS	171
TABLE 111 CYTOMEDIX INC. RECENT DEVELOPMENTS	172
TABLE 112 CYTORI THERAPEUTICS INC. RECENT DEVELOPMENTS	173
TABLE 113 CYTORI THERAPEUTICS FINANCIALS, 2011-2013 (\$ MILLIONS/%)	173
TABLE 114 GENZYME RECENT DEVELOPMENTS	174
TABLE 115 GENZYME FINANCIALS, 2011-2013 (\$ MILLIONS/%)	174
TABLE 116 KINETIC CONCEPTS INC. RECENT DEVELOPMENTS	175
TABLE 117 KINETICS CONCEPTS FINANCIALS, 2011-2013 (\$ MILLIONS/%)	175
TABLE 118 WRIGHT MEDICAL TECHNOLOGY INC. RECENT DEVELOPMENTS	178
TABLE 119 WRIGHT MEDICAL TECHNOLOGY FINANCIALS, 2011-2013 (\$ MILLIONS/%)	178
TABLE 120 NORTH AMERICAN PATENTS	180
TABLE 121 EUROPEAN PATENTS	181
TABLE 122 JAPANESE PATENTS	182

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, 2013-2019 (\$ MILLIONS)	7
FIGURE 1 TISSUE-ENGINEERING STRATEGIES	12
FIGURE 2 POTENTIAL NANOTECHNOLOGY APPLICATIONS	14
FIGURE 3 PORTER'S FIVE FORCE MODEL FOR TISSUE ENGINEERING PRODUCTS	24
FIGURE 4 GROWTH IN DISEASE TREATED VERSUS CLINICAL TRIALS, 2008-2012 (NO. OF TRIALS AND TREATMENTS)	31
FIGURE 5 PATHWAY FOR DISSEMINATION OF REGENERATIVE MEDICINE	133
FIGURE 6 KEY COMPETITIVE STRATEGIES*, 2010-2014 (%)	142
FIGURE 7 APPROVAL STRATEGY BY COMPANY, 2010-2014 (%)	144
FIGURE 8 AGREEMENTS, MERGERS AND ACQUISITIONS, BY COMPANY, 2010-2014 (%)	147
FIGURE 9 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%)	150
FIGURE 10 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%)	153
FIGURE 11 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)	154
FIGURE 12 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)	155
FIGURE 13 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)	156
FIGURE 14 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)	158
FIGURE 15 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)	159